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Abstract
Purpose: To examine the utility of electronic health records from a routine care
setting in assessing comparative effectiveness of fourth‐line anti‐hypertensive drugs
to treat resistant hypertension.
Methods: We conducted a cohort study using the Clinical Practice Research
Datalink: a repository of electronic health records from UK primary care. We iden-
tified patients newly prescribed fourth‐line anti‐hypertensive drugs (aldosterone
antagonist , beta‐blocker, or alpha‐blocker). Using propensity score–adjusted Cox
proportional hazards models, we compared the incidence of the primary outcome
(composite of all‐cause mortality, stroke, and myocardial infarction) between
patients on different fourth‐line drugs. AA was the reference drug in all compari-
sons. Secondary outcomes were individual components of the primary outcome,
blood pressure changes, and heart failure. We used a negative control outcome,
Herpes Zoster, to detect unmeasured confounding.
Results: Overall, 8639 patients were included. In propensity score–adjusted
analyses, the hazard ratio for the primary outcome was 0.81 (95% CI, 0.55‐1.19) for
beta‐blockers and 0.68 (95% CI, 0.46‐0.96) for alpha‐blockers versus AA. Findings
for individual cardiovascular outcomes trended in a more plausible direction, albeit
imprecise. A trend for a protective effect for Herpes Zoster across both comparisons
was seen.
Conclusions: A higher rate of all‐cause death in the AA group was likely due to
unmeasured confounding in our analysis of the composite primary outcome,
supported by our negative outcome analysis. Results for cardiovascular outcomes
were plausible, but imprecise due to small cohort sizes and a low number of observed
outcomes.
KEYWORDS
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1 | INTRODUCTION
Hypertension, or high blood pressure (BP), is a leading risk factor for
cardiovascular and cerebrovascular deaths.1 These deaths constitute
more than 30% of all deaths globally, and with hypertension being
highly prevalent, have been declared a global public health crisis.2,3
Resistant hypertension (RH) is defined as BP that remains
≥140/90mmHg despite being treated with maximum, or best tolerated
doses, of three or more anti‐hypertensive drugs, one of which should
be a diuretic.4-6 Almost 7% of the treated hypertensive population in
the United Kingdom has RH, representing approximately 800 000 peo-
ple.7 Those with RH have worse health outcomes than those with
“standard” hypertension, which double the risk of cardiovascular
events.8 Thus, the prevention and treatment of RH is of great impor-
tance in reducing the burden of cardiovascular disease and mortality.1,9
RH has traditionally been an area of unmet treatment need.10
However, PATHWAY‐2, a recent clinical trial, of 285 patients with
RH has provided evidence that spironolactone, an aldosterone antag-
onist (AA) with diuretic activity, is better at reducing BP in comparison
to a beta‐blocker,an alpha‐blocker, 11 The trial, although badly needed,
was somewhat limited in that it looked at reductions in BP as opposed
to “hard” clinical outcomes of major interest such as myocardial infarc-
tion, stroke, and death. Furthermore, patients in the trial were
followed for 12 weeks, which is a short amount of time given that
the complications of high BP develop over longer time periods. Such
limitations are inherent in many randomised trials where financial
costs, logistics, and ethical considerations often mean larger scale trials
with longer follow up are not feasible.
Patients, care providers, and regulators are increasingly seeking
detailed evidence of medication effects in routine care settings, but
optimal, validmethods for conducting this kind of research are currently
uncertain.12 Electronic health record (EHR) data offer an opportunity to
determine whether the comparative effectiveness of fourth‐line anti‐
hypertensive drugs can be investigated in a routine care setting.13 Data
for large heterogeneous populations allow capture of rare outcomes
such as myocardial infarction, stroke, and death over longer periods of
time than that can be typically used in randomised controlled trials.
However, different anti‐hypertensive drugs can be used preferentially
depending on a patient's adverse drug event profile, their comorbidities,
and physician preference.14,15 Whether EHR data allow accurate
capture of this confounding by indication remains to be examined.
Thus, we used EHR data to study how BP changes following initi-
ation of different fourth‐line anti‐hypertensive drugs and to assess
whether we can reliably use routine care data to inform on long‐term
clinical outcomes in this context.
2 | METHODS
2.1 | Study design and data
We conducted a retrospective cohort study, using the Clinical Practice
Research Database (CPRD‐GOLD), a nationally representative
repository of de‐identified EHRs from primary care in the United King-
dom. CPRD‐GOLD holds data on demographic information, health‐
related behaviours, test results including BP readings, diagnoses, and
prescriptions for more than 11 million people in more than 670 prac-
tices across the United Kingdom since 1987.16 It is one of the largest
databases of longitudinal medical records from primary care globally
and has been extensively validated.17 Data quality are monitored by
CPRD internal processes.
2.2 | Cohort
Patients were eligible for cohort entry from the latest of practice up‐
to‐standard date, patients current registration date plus 1 year,
patients' 18th birthday, or study start 2 February 1998. We identified
patients who initiated a fourth‐line anti‐hypertensive, AA, beta‐
blocker, or alpha‐blocker between 1998 and 2016. To mirror guide-
line‐defined RH,14 we required that the patient's base regimen com-
prised an angiotensin converting enzyme‐inhibitor/angiotensin
receptor blocker (ACE‐I/ARB), calcium channel blocker (CCB), and a
thiazide diuretic. To resemble the PATHWAY‐2 clinical trial11 and to
minimise confounding by indication, we applied the following exclu-
sion criteria: BP <140/90mmHg serum potassium >5.5mmol/L, pulse
rate <55 or > 120 beats per minute, estimated glomerular filtration
KEY POINTS
• We compared the effectiveness of fourth‐line alpha‐
blockers and beta‐blockers to aldosterone antagonists in
resistant hypertension. Aldosterone antagonists (AA)
were the reference because they were found to be the
most effective fourth‐line drug at lowering blood
pressure in a recent trial.
• Effectiveness was measured by a composite primary
outcome: all‐cause death, myocardial infarction, and
stroke. Secondary outcomes included the individual
components of the primary outcome, heart failure, and
changes in blood pressure. We used a negative control
outcome to help identify if confounding/bias was
present.
• We found that those exposed to alpha‐blockers and
beta‐blockers were at a decreased, albeit imprecise, risk
of the primary outcome in comparison to those exposed
to aldosterone antagonists. A higher rate of all‐cause
death in the AA group was likely due to unmeasured
confounding in our analysis of the composite primary
outcome, supported by our negative outcome analysis.
• Results for cardiovascular outcomes and blood pressure
changes were plausible, indicating less confounding for
specific outcomes.
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rate (eGFR) <45mL/min/1.73m2, or a diagnosis of heart failure. To
ensure that patients were continuing concurrent treatment with all
four drugs as opposed to switching, we required repeat prescriptions
of all four drugs within 6 months of initiating the fourth‐line drug.
The date on which continued use of four drugs was confirmed was
referred to as the index date.
We attempted to exclude patients who displayed poor medication
adherence behaviour, because this has been noted as a main cause of
many cases of apparent RH.18,19 In the absence of dispensing records,
which are typically used to measure adherence at the population level,
we instead used prescribing records to estimate a proxy for drug
adherence. We measured this proxy for each patients' drug regimen
in the 1‐year period prior to initiating the fourth‐line drug. Using pre-
scription dates and computed days' supply prescribed, we calculated
proxy adherence as the number of days covered by the drug divided
by the number of days in the observation period. We accounted for
leftover days' supply from previous prescriptions by adding to the next
supply. We calculated average adherence across all three drugs and
then categorised as adherent or not based on an 80% threshold.20 If
patients did not meet our definition for proxy adherence, they were
excluded.
2.3 | Outcomes
The primary outcome was a composite of first myocardial infarction,
stroke, and all‐cause mortality. This three‐component composite out-
come is frequently used in trials of cardiovascular outcomes and is sta-
tistically helpful in instances where low event rates might occur for a
single outcome.21,22 Secondary outcomes included change in systolic
BP, heart failure, end‐stage renal failure, myocardial infarction, stroke,
and all‐causemortality. All‐cause mortality was included because it is
assumed to be an “ideal” endpoint given that it can be determined
without ascertainment bias and that preventing mortality is the
ultimate goal of many drug treatments. Adverse outcomes were
hyperkalaemia defined as serum potassium ≥6 mmol/Land gyneco-
mastia. We used incidence of Herpes Zoster as a negative control
outcome to explore unmeasured confounding between fourth‐
lineanti‐hypertensive groups (see the Supporting Information for
codes used to identify all outcomes).23
2.4 | Covariates
We used data on the following covariates: age, sex and lifestyle fac-
tors; smoking, alcohol use, and body mass index. The closest
records to fourth‐lineanti‐hypertensive initiation date were used for
determining lifestyle factors using existing algorithms.24 Other med-
ication use included prior use of statins, anti‐platelet agents, proton
pump inhibitors, insulin, and loop diuretics. We also captured medi-
cation usage from multiple British National Formulary chapters in
the year prior to initiation to indicate polypharmacy. We categorised
as usage of drugs from 0 to 4 chapters, 5 to 8 chapters, and ≥9
chapters. We accounted for the following comorbidities: diabetes,
prior myocardial infarction, prior stroke, arrhythmia, peripheral vas-
cular disease, cancer, depression, and chronic obstructive pulmonary
disease. To capture health service use, we constructed a variable
indicating how often a patient used primary care services in the year
prior to initiation. This was categorised as 0 to 9 consultations, 10 to
19 consultations, 20 to 29 consultations, 30 to 39 consultations, and
≥40 consultations. We calculated baseline eGFR (45‐60mL/min/
1.73m2 or >60mL/min/1.73m2) using the most recent creatinine
value from CPRD data 1 year prior to fourth‐linedrug initiation and
the Chronic Kidney Disease Epidemiology Collaboration (CKD‐EPI)
equation.25 Serum potassium at baseline was categorised as
<5mmol/Lor 5‐5.5mmol/L. We included morbidities indicative of a
secondary cause of hypertension: phaeochromocytoma, sleep
apnoea, aldosteronism, Cushing's syndrome, and renal causes. We
also included drugs that are known to increase BP in the year
prior to initiation date: non‐steroidalanti‐inflammatorydrugs,
tacrolimus/ciclosporin, erythropoietin, high dose steroids (equivalent
to 20‐mgprednisolone daily) for at least 2 weeks, and the oral contra-
ceptive pill. Lastly, we included information on symptoms and testing
that could suggest a presence of heart failure, shortness of breath,
peripheral oedema, and evidence of echocardiograph. We described
data for ethnicity but did not include in analytical models due to more
than 50% missingness.26
2.5 | Statistics
We analysed each drug comparison separately: beta‐blockers versus
AA and alpha‐blockers versus AA. There were approximately 20 to
25% missing data for baseline categories of eGFR and serum potas-
sium and approximately 5% missing data for lifestyle variables:
smoking, alcohol consumption, and body mass index. To maximise
sample size, we imputed missing data under the missing at random
assumption.27 In the imputation model, we included all explanatory
variables listed above, including the outcome variable and the Nel-
son‐Aalenestimate of the cumulative hazard to the survival time for
each individual outcome assessment.27,28 We conducted diagnostics
using the midiagplots function in Stata.29 Within each of the 10
imputed datasets and using all the covariates listed above, we calcu-
lated a propensity score, wherein AA was the reference group for drug
comparison (Appendix A). We then used this propensity score in an
adjusted Cox Proportional Hazards model to estimate the hazard ratio
and 95% confidence interval for each outcome, and then combined
treatment effects across each imputed dataset to get one overall esti-
mate.30 For changes in systolic BP, we used cubic spline mixed models
with a random intercept for each patient. Such models allow for corre-
lations within patients for BP results and also accommodate the unbal-
anced nature of BP readings in the data.31 There was a median of 17
(IQR 9‐29 BP measurements available during follow‐up for each
patient. Patients without a BP measurement during follow‐upwere
dropped from the BP analysis (n=133).
In all analyses, follow‐up started on the index date, ie, the date on
which use of four concurrent anti‐hypertensive drugs was confirmed.
SINNOTT ET AL. 3
Follow‐upcontinued until the patient experienced an outcome, death,
withdrew from the general practice, last data collection date for each
practice, end of study (February 2016) or 3‐yearpost index date,
whichever occurred first. All main analyses were intention to treat.
2.6 | Sensitivity and subgroup analyses
We conducted subgroup analyses, whereby the main analysis was
stratified by age, gender, diabetes, CKD, and baseline systolic BP.
We also conducted analyses where we applied (1) further PATH-
WAY‐2 exclusion criteria and (2) less stringent exclusion criteria
removing criteria relating to BP, serum potassium, pulse rate, eGFR,
and diagnosed heart failure.11 We also conducted stratified analyses
according to arrhythmia at baseline given that some of the drugs used
to meet the definition of RH could also be used to treat arrhythmias.
We carried out a sensitivity analysis, whereby follow‐up started from
date of initiation (ie, the date of fourth drug initiation) as opposed to
from index date (date on which continued use of four drugs was con-
firmed). Our rationale was that this analysis would capture adverse
events and outcomes directly after initiation in patients who may
not have had a repeat prescription of the fourth drug helping us to
understand, to some degree, the number of events our main analysis
may have missed. An extension of this analysis considered BP changes
in patients who had evidence of repeat prescriptions of fourth‐
linedrugs, but with follow‐upbeginning on date of initiation. This
analysis aimed to assess whether BP changes in this observational
cohort are similar to those found in PATHWAY‐2.11 We also con-
ducted sensitivity analyses in which we censored follow‐upwhen the
patient discontinued their fourth‐lineanti‐hypertensivedrug or
switched to a different fourth‐linedrug. Finally, we conducted a com-
plete‐caseanalysis including only patients who did not require imputa-
tion of covariates.
3 | RESULTS
From more than 2 million users of anti‐hypertensive drugs, we identi-
fied 8639 people who were treated with an ACE‐I/ARBplus a CCB
plus a diuretic prior to addition of fourth‐lineanti‐hypertensive drug
(Figure 1). The mean age of included patients was 64.9 years (SD
11.2), and the population was 43.4% female. Diabetes was most prev-
alent in patients initiating alpha‐blockers (Table 1). Those initiating an
AA as a fourth‐linedrug had the highest prevalence of
tests/symptomsindicating heart failure, eg, evidence of an
echocardiograph, shortness of breath, and peripheral oedema. This
group also had the highest prevalence of non‐
cardiovascularcomorbidities. Systolic and diastolic BP at initiation of
fourth‐lineanti‐hypertensivewere highest in patients initiating alpha‐
blockers (Table 1). A table comparing common baseline characteristics
for PATHWAY‐2 and this observational cohort is provided in Appen-
dix B in the Supporting Information.
FIGURE 1 A flowchart demonstrating study
inclusion and exclusion criteria
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3.1 | Primary outcome analyses
In separate analyses comparing beta‐blockersand alpha‐blockersto AA,
a protective effect for the primary outcome (composite of first myo-
cardial infarction, stroke, and all‐causemortality) was observed across
both comparisons, although the 95% confidence intervals (95% CI)
approached the null. After adjusting for the propensity score, there
was no change in the direction of the hazard ratios and the 95% CI
continued to cross or approach the null (Table 2). Within 3 years of
index date 115/2869 (4.0%) users of beta‐blockers had died, 241/
5420 (4.4%) users of alpha‐blockers had died, and 24/350 (6.9%) users
of AA had died.
3.2 | Secondary Outcome analyses
3.2.1 | BP changes
At 12 weeks, systolic BP was approximately 2mmHg higher in the
beta‐blockerand alpha‐blockergroups in comparison to AA (Figure 2
and Table 3). However, by 2‐yearfollow‐up, there was a negligible dif-
ference in systolic BP. From initiation date (as opposed to index date),
there were differences of approximately 3mmHg in the beta‐
blockerand alpha‐blockergroups in comparison to AA, but by 2 years,
there was negligible difference (Appendix C).
3.2.2 | Secondary clinical outcomes
A trend towards increased stroke and heart failure for those initiating
beta‐blockersand alpha‐blockers in comparison to AA was observed,
although the 95% CI encompassed the null effect (Table 4). In con-
trast, a trend towards decreased death for users of beta‐blockersand
alpha‐blockerswas observed, but again, the 95% CI encompassed the
null effect. The number of outcomes observed for end stage renal dis-
ease was low (Appendix D), and thus, we did not formally analyse.
3.3 | Adverse outcomes
There was protective effect for hyperkalaemia when beta‐blockersand
alpha‐blockerswere compared with AA (Appendix E). The number of
outcomes observed for gynecomastia was low (Appendix D), and we
did not formally analyse.
3.4 | Negative outcome
Although imprecise, there was a trend towards a protective effect
when beta‐blockersand alpha‐blockerswere compared with AA for
Herpes Zoster (Table 4).
3.5 | Subgroup and sensitivity analyses
The 95% CI for all subgroup analyses overlapped with the 95% CI for
the main effect; however, there was a trend for those who were
<60years and those who had diabetes to have increased hazard for
the primary outcome than those without, and this was generally con-
sistent across both drug comparisons (Appendix F). There was no
strong evidence to suggest a difference in hazard for the primary out-
come when stratified by arrhythmia at time of initiation (Appendix G).
In a sensitivity analysis, we censored patients when they either
discontinued their fourth‐linedrug or started another fourth‐linedrug.
The confidence limits overlapped with those in the main analysis
(Appendix H). We also examined the hazard for the primary outcome
and adverse outcomes from initiation date (as opposed to index date).
For the primary outcome, the protective effect observed for the pri-
mary outcome was exaggerated for those initiating beta‐blockersand
alpha‐blockersin comparison to the main analysis (Appendix I). For
adverse outcomes, the results were similar to those reported from
index date (Appendix E). The results of the complete‐caseanalysis
were similar to the main analysis (Appendix J).
4 | DISCUSSION
In this cohort study of 8639 patients with RH, we found inconclusive
results for the association between beta‐blockersand alpha‐
blockerscompared with AA and the occurrence of the combined out-
come of myocardial infarction, stroke, and all‐causemortality. For sec-
ondary outcomes (heart failure, myocardial infarction, stroke, and all‐
causemortality), the magnitude and direction of the hazard ratios for
some cardiovascular endpoints appeared plausible, although imprecise
due to low numbers of outcomes. The results for all‐causemortality
suggest the presence of uncontrolled confounding, a finding that
was supported by the negative control outcome analysis.
We found that patients prescribed AA as a fourth‐
lineantihypertensive in RH had systolic BP values approximately
2mmHg lower than those in patients prescribed beta‐blockersand
alpha‐blockersat 12‐weekpost index date, and 3mmHg lower post ini-
tiation date. In the PATHWAY‐2 clinical trial, an average difference of
4mmHg (clinic BP) for the same comparisons was found, averaged
across 6‐and 12‐weekfollow‐upvisits.11 Over the duration of follow‐
upin our study, the differences in systolic BP between the comparison
drugs diminished to negligible for the beta‐blockerand alpha‐
blockercomparisons.
Other observational studies have compared different fourth‐
lineanti‐hypertensivedrugs and found reductions in systolic BP of on
average 12mmHg, favouring AA.32 These previous observational stud-
ies were carried out in hospitals; thus, the identification and inclusion
processes were not similar to the algorithms we used. Additionally,
investigators in both randomized controlled trials and cohort studies
using primary data collection have control over the frequency and
method of BP measurement, which is not possible in EHR data. As
seen from Table 3, between 70 and 80% of patients in our study had
BP measurements within 12 weeks of index date.
Based on the findings of PATHWAY‐2, and our findings for BP
reductions, it could be reasonably expected that cardiovascular out-
comes occur at a lower rate in those exposed to AA. 11,33 Our results
for the primary outcome do not reflect this expectation. Rather than
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TABLE 1 Baseline characteristics of patients initiating fourth‐line anti‐hypertensive drugs
Alpha‐blockers, % Aldosterone Antagonist n, % Beta‐blocker n, %
No of Patients 5420 350 2869
Females 2244 (41.4) 182 (52.0) 1324 (46.1)
Age, Years
<50 580 (10.7) 33 ( 9.4) 279 ( 9.7)
50‐59 1184 (21.8) 67 (19.1) 549 (19.1)
60‐64 823 (15.2) 45 (12.9) 379 (13.2)
65‐69 954 (17.6) 58 (16.6) 464 (16.2)
70‐74 780 (14.4) 58 (16.6) 474 (16.5)
75‐79 603 (11.1) 44 (12.6) 391 (13.6)
80+ 496 ( 9.2) 45 (12.9) 333 (11.6)
Ethnicity
White 2177 (40.2) 142 (40.6) 1172 (40.9)
South Asian 51 (0.9) na 35 (1.2)
Black 90 (1.7) 6 (1.7) 34 (1.2)
Other/mixed 30 (0.6) na 13 (0.5)
Missing 3072 (56.7) 199 (56.9) 1615 (56.3)
Smoking
Non‐smoking 1913 (35.3) 136 (38.9) 1145 (39.9)
Current smoker 870 (16.1) 32 (9.1) 417 (14.5)
Ex‐smoker 2452 (45.2) 161 (46) 1232 (42.9)
Missing 185 (3.4) 21 (6) 75 (2.6)
Alcohol
Non‐drinking 612 (11.3) 38 (10.9) 331 (11.5)
Current drinker 3917 (72.3) 240 (68.6) 2094 (73)
Ex drinker 565 (10.4) 42 (12) 268 (9.3)
Missing 326 (6) 30 (8.6) 176 (6.1)
Body mass index (kg/m2)
Underweight <18.5 19 (0.4) na 10 (0.4)
Healthy_weight 18.5‐24.9 729 (13.5) 40 (11.4) 466 (16.2)
Overweight 25‐29.9 1764 (32.6) 93 (26.6) 977 (34.1)
Obesity ≥30 2629 (48.5) 190 (54.3) 1259 (43.9)
Missing 279 (5.2) 24 (6.9) 157(5.5)
Comorbidities
Myocardial Infarction 141 (2.6) 17 (4.9) 131 (4.6)
Stroke 377 (7.0) 29 ( 8.3) 224 (7.8)
Peripheral vascular disease 382 (7.0) 23 (6.6) 147 (5.1)
Diabetes 1939 (35.8) 115 (32.9) 743 (25.9)
Depression 444 (8.2) 42 (12.0) 203 (7.1)
COPD 309 (5.7) 28 (8.0) 90 (3.1)
Cancer 527 (9.7) 46 (13.1) 309 (10.8)
Secondary causes of hypertensiona 173 (3.2) 23 (6.6) 75 (2.6)
Indicators of possible heart failure
Echocardiograph 528 ( 9.7) 73 (20.9) 332 (11.6)
Shortness of breath 845 (15.6) 111 (31.7) 355 (12.4)
(Continues)
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TABLE 1 (Continued)
Alpha‐blockers, % Aldosterone Antagonist n, % Beta‐blocker n, %
No of Patients 5420 350 2869
Peripheral oedema 389 ( 7.2) 35 (10.0) 210 ( 7.3)
eGFR (mL/min)
≥60 3488 (64.4) 220 (62.9) 1736 (60.5)
45‐59 992 (18.3) 70 (20.0) 523 (18.2)
Missing 940 (17.3) 60 (17.1) 610 (21.3)
Drugs
Antiplatelet 2420 (44.6) 166 (47.4) 1241 (43.3)
Statins 3055 (56.4) 204 (58.3) 1479 (51.6)
Proton pump inhibitors 1793 (33.1) 158 (45.1) 983 (34.3)
Insulin 439 ( 8.1) 27 ( 7.7) 148 ( 5.2)
Loop diuretic 705 (13.0) 85 (24.3) 334 (11.6)
BP increasing drugsb 234 ( 4.3) 18 ( 5.1) 113 ( 3.9)
Number of unique consultations
0‐9 1947 (35.9) 82 (23.4) 1056 (36.8)
10‐19 2335 (43.1) 144 (41.1) 1187 (41.4)
20‐29 757 (14) 88 (25.1) 407 (14.2)
30‐39 211 (3.9) 16 (4.6) 120 (4.2)
≥40 170 (3.1) 20 (5.7) 99 (3.5)
Number of unique BNF chapters
0‐4 3043 (56.1) 157 (44.9) 1669 (58.2)
5‐8 2108 (38.9) 158 (45.1) 1085 (37.8)
≥9 269 (5.0) 35 (10.0) 115 (4.0)
Physiological parameters mean (SD)
Potassium 4.27 (0.46) 4.15 (0.45) 4.28 (0.45)
Missing n, % 1144 (21.1) 76 (21.7) 715 (24.8)
Systolic BP 163.1 (15.9) 161.8 (16.6) 161.2 (16.9)
Missing n, % 45 (0.8) 11 (3.1) 54 (1.9)
Diastolic BP 86.4 (12.4) 84.8 (12.5) 85.6 (12.6)
Missing n, % 45 (0.8) 11 (3.1) 54 (1.9)
Pulse rate 78.9 (13.1) 79.1 (13.8) 84.1 (14.6)
Missing n, % 4694 (86.3) 278 (79.4) 2392 (83.1)
Note. “na” refers to cell sizes too small to report in accordance with our data agreements.
Abbreviations: BNF, British National Formulary; BP, blood pressure; COPD, chronic obstructive pulmonary disease; SD, standard deviation.
aPhaeochromocytoma, sleep apnoea, aldosteronism, Cushing's syndrome, and renal causes measured using all available data.
bNon‐steroidal anti‐inflammatory drugs, tacrolimus/ciclosporin, erythropoietin, high dose steroids (equivalent to 20mg prednisolone daily for at least 2
weeks), and the oral contraceptive pill in the 365‐day period prior to initiation.
TABLE 2 Crude and adjusted hazard ratios for the primary outcome
N Outcomes Crude HR (95% CI) Adjusted HR (95% CI)
Beta‐blockers vs aldosterone antagonists 2827 204 0.69 (0.47‐0.99) 0.81 (0.55‐1.19)
Alpha‐blockers vs aldosterone antagonists 5215 334 0.63 (0.44‐0.91) 0.68 (0.46‐0.96)
Crude: age‐ and gender‐adjusted only.
Note. Adjusted: propensity score adjusted.
Abbreviation: HR, hazard ratio.
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FIGURE 2 Three‐year blood pressure changes from index date for (A) beta‐blockers vs aldosterone antagonists and (B) alpha‐blockers vs
aldosterone antagonists [Colour figure can be viewed at wileyonlinelibrary.com]
TABLE 3 Systolic blood pressure from index date
% with BP Readings
Beta‐blockers
Systolic BP mmHg (95% CI) % with BP Readings
Aldosterone Antagonists
Systolic BP mmHg (95% CI)
At baseline 100 155.2 (154.6‐155.8) 100 154.4 (152.6‐156.2)
At 12 week 76.0 147.8 (147.2‐148.4) 72.0 146.1 (144.4‐147.7)
At 1 year 96.1 145.9 (145.2‐146.5) 94.0 143.5 (141.7‐145.3)
At 2 years 98.0 143.5 (142.9‐144.1) 96.3 143.9 (142‐145.7)
At 3 years 98.3 143.4 (142.5‐144.3) 96.9 143.1 (140.4‐145.7)
Alpha‐blockers
Systolic BP mmHg (95% CI)
Aldosterone Antagonists
Systolic BP mmHg (95% CI)
At baseline 100 156.4 (156‐156.9) 100 154.7 (153‐156.5)
At 12 weeks 80.1 148.6 (148.2‐149) 72.0 146.2 (144.6‐147.8)
At 1 year 97.4 146.2 (145.8‐146.6) 94.0 143.7 (142‐145.5)
At 2 years 98.6 143.8 (143.3‐144.2) 96.3 144 (142.3‐145.8)
At 3 years 98.7 144.5 (143.9‐145.1) 96.9 144 (141.4‐146.6)
Note. Weekly and yearly time points refer to time passed since index date. Data are from propensity score–adjusted cubic spline mixed models.
Abbreviations: BP, blood pressure; CI, confidence interval.
TABLE 4 Hazard ratios and 95% CI for secondary outcomes and negative outcome in each fourth‐line anti‐hypertensive comparison
Beta‐blockers vs Aldosterone Antagonists Alpha‐blockers vs Aldosterone Antagonists
N Outcome HR (95% CI) n Outcome HR (95% CI)
Death 3217 142 0.68 (0.41‐1.11) 5768 271 0.65 (0.42‐1.01)
Stroke 2960 58 2.50 (0.57‐10.91) 5353 78 2.64 (0.63‐11.05)
MI 3059 46 0.95 (0.37‐2.46) 5607 86 1.05 (0.45‐2.48)
Heart failure 3192 67 2.68 (0.82‐8.81) 5759 98 2.35 (0.71‐7.80)
Negative outcome: Herpes Zoster 2983 55 0.67 (0.28‐1.58) 5400 94 0.78 (0.34‐1.78)
Note. Analyses are propensity score adjusted.
Abbreviation: HR, hazard ratio; MI, myocardial Infarction.
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detract from the utility of data from routine care settings to carry out
comparative effectiveness analyses, it is important to explore why
our study did not produce the expected results.
We pragmatically used a composite primary outcome to achieve an
adequate number of events for a powered analysis. However, includ-
ing all‐causemortality in the primary outcome lead to a confounded
association. Our negative control analysis, whilst having low statistical
power, implied a lower risk of herpes zoster with beta‐blockersand
alpha‐blockerswhen compared with AA, when no association should
be expected, reaffirming our suspicion of residual confounding. In
other words, users of AA were, at baseline, different in terms of their
morbidity profile and at greater risk of death than users of the other
medication groups. This problem is in theory redeemable if informa-
tion on factors associated with both the exposure and closeness to
death (ie, confounders) can be measured and adjusted for, eg, undiag-
nosed heart failure or frailty. We attempted to adjust for undiagnosed
heart failure in our analyses by using proxy variables, breathlessness,
peripheral oedema, and history of echocardiography. These covariates
were imbalanced between the medication groups, with higher preva-
lence among AA users. Unfortunately, these symptoms/testsare likely
to be a limited proxy for heart failure and may not be coded
completely, thus limiting their potential in confounding adjustment.
We believe that frailty was imbalanced between the medication
groups as indicated by the higher prevalence of several comorbidities,
medication utilisation, and health service utilisation covariates in the
AA group compared with the other medication groups. Information
on key indicators of frailty is not readily available in EHR data, eg, grip
strength, and leads to incomplete capture of this important confound-
ing mechanism between the exposure and all‐causedeath.34
In contrast, the direction of our results for some individual cardio-
vascular outcomes appeared plausible, albeit imprecise. Imprecision is
likely a direct result of small cohort sizes and a low number of outcomes.
Our cohort sizes may have been conservatively small; in the absence of
a formal diagnosis code, we applied a strict definition for RH based on
medication usage, diagnosis codes for hypertension, and an estimate
of proxy adherence, along with multiple exclusion criteria to remove
patients who may have been using a similar medication regimen for
the treatment of heart failure. Our method of measuring adherence
likely underestimated true adherence,35,36 however was the most prag-
matic option available in the absence of linked dispensing data.
An additional limitation to this study is that those with RH are not
a straightforward population to isolate from EHR data. Indeed, even in
clinical settings, identification of those with true RH is challenging.18,19
Therefore, it is possible that some of the included patients were not
“true” RH patients; some may have had the medication patterns we
required and may have had coded hypertension but may also have
been using some anti‐hypertensivedrugs for indications other than
hypertension. We carried out multiple sensitivity analyses to test our
identification process and to mimic the PATHWAY‐2 population as
closely as possible; however, these yielded results similar to the main
analysis.
Lastly, we did not include data on ethnicity in our propensity score
models due to missingness.26 However, the CPRD population is
representative of the UK population in terms of ethnicity. Further-
more, in a sensitivity analysis restricted to people of white ethnicity,
we found similar results to the main analysis.
Despite the above limitations, some strengths do exist. This is the
first study, randomised or observational, to examine the comparative
effectiveness of fourth‐linedrugs in RH with regard to the incidence
of clinical outcomes. We conducted a range of additional analyses,
which help to understand the limitations of our approach and help
to signpost future efforts that could improve upon our study.
5 | CONCLUSION
We used EHR data to investigate the comparative effectiveness of dif-
ferent fourth‐lineanti‐hypertensivedrugs used to treat RH in routine
care using an observational design with propensity score adjustment.
The findings of a recent clinical trial, PATHWAY‐2, imply that
outcomes should occur at a lower rate in those exposed to AA in com-
parison to other fourth‐lineanti‐hypertensivedrugs.11 We found incon-
clusive results for the primary outcome. We suspect that this occurred
due to unmeasured confounding.
Conversely, the direction and magnitude of results for some
secondary cardiovascular outcomes did not appear to be confounded
to the same extent and are somewhat more plausible, albeit with wide
confidence intervals.
Despite our findings, addressing this research question in routine
health care data is not without future potential. Next efforts using
alternative data sources, data linkage for better capture of comorbid-
ities diagnosed or managed in secondary care, and further methodo-
logical development such as more complete capture of data on
characteristics such as frailty, which may help overcome
confounding.
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